三方:生物仿制药如何降低成本,扩大获取,提高利率
Tina M Seekamp1, Michael Hamacher2, Jason A Kemper3
1Supply Chain Management, Mayo Clinic, Rochester, Minnesota.
Journal of the American Pharmacists Association : JAPhA
|October 29, 2025
概括
医疗保险患者在实施生物类药物优先战略后,参考生物使用量减少了47%. 这种转变降低了成本,增加了患者的获取,并改善了卫生系统的财务利率.
科学领域:
- 卫生经济学 卫生经济学
- 制药政策 制药政策
- 提高质量 提高科学 提高质量
背景情况:
- 传统医疗保险服务费 (FFS) 涵盖没有事先授权 (PA) 的参考生物药物和生物类似药.
- 生物类药物为参考生物制剂提供了经济,安全和有效的替代品.
研究的目的:
- 将Medicare FFS患者在瘤学中使用参考生物药物的使用量减少50%.
- 为了减少梅奥诊所社区负责护理组织 (MCC ACO) 的支出,并实现机构成本节省.
- 通过增加生物类似药的利用来提高收入.
主要方法:
- 实施了质量改进 (QI) 框架,以扩大生物类药物优先战略.
- 利用有针对性的电子健康记录 (EHR) 报告来识别使用参考生物制剂的医疗保险患者,当生物类似药可用时.
- 通过药剂师和医生推广和教育,促进患者转换为更低成本,更喜欢配方药的生物类药物.
主要成果:
- 在医疗保险患者中减少了参考生物使用的47%.
- 减少了MCC ACO支出262万美元,并减少了每个用户每月的支出13.9%.
- 改善了超过220万美元的药物利率,每个药物类别的模型患者数量为1000人.
结论:
- 质量改善举措有效地减少了医疗保险患者的参考生物使用量.
- 转向生物仿制药成功降低了医疗保健支出,并增加了患者的获取.
- 该战略改善了财务利,证明了采用生物类似药的经济效益.
相关概念视频
Drug Products: Biologics, Biosimilars and Interchangeables
229
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
229
Bioequivalence: Overview
1.8K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.8K
Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems
171
Body:Bioavailability is a critical pharmacological concept that measures the extent and rate at which an active drug ingredient or therapeutic moiety enters the systemic circulation, remaining unchanged. It's a pivotal factor in determining a drug's efficacy and safety.The Biopharmaceutics Classification System (BCS) plays an essential role in drug development by categorizing drugs into four classes based on their solubility and permeability. This classification aids in understanding drug...
171
Bioavailability Enhancement: Drug Permeability Enhancement
183
Body:After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt...
183
Issues And Trends In Healthcare Delivery System
6.1K
The issues and trends in healthcare delivery are constantly changing. The COVID-19 pandemic is one recent issue that wreaked havoc on healthcare systems, causing a shortage of healthcare workers, high demand for medicines and supplies, and increased medical expenditure due to a lack of insurance. Other issues include rising healthcare costs and care fragmentation.
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
6.1K
Bioequivalence of Drugs: Drugs with Multiple Indications
147
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
147


